Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT05008055 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Interventions

DRUG: Capivasertib

Sponsor

AstraZeneca

Collaborators

[object Object]